MyMD Pharma rebrands to TNF Pharmaceuticals; ticker changes to TNFA on Nasdaq

Q/C TECHNOLOGIES, INC.

Name changed from MyMD Pharmaceuticals to TNF Pharmaceuticals effective July 22, 2024.
Common stock began trading under new ticker 'TNFA' on Nasdaq effective July 24, 2024, replacing 'MYMD'.
Rebranding aligns with therapeutic focus on TNF-alpha inhibition; lead candidate MYMD-1 unchanged.
No change to CUSIP or shareholder action required; stockholder approval was not needed.
Company plans mid-stage clinical trials of MYMD-1 for sarcopenia following positive Phase 2 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.